warrants Applied DNA Prices $12M Public Stock, Warrant Offering The company, which develops molecular diagnostics and manufactures DNA, closed a roughly $4.2 million registered direct stock offering earlier this year. Progenity Enters $25M Private Placement The company will issue units representing an aggregate of shares of common stock and warrants to purchase stock shares at an aggregate purchase price of $5.72. OpGen Enters $25M Direct Offering Agreement A single healthcare-focused investor will purchase 2.78 million shares of common stock, 5.55 million prefunded warrants, and an additional 4.17 million shares of common stock. OpGen Prices $9.4M Stock, Warrant Offering OpGen said it intends to use the proceeds of the offering to complete its acquisition of German molecular diagnostics firm Curetis, among other things. OpGen Plans $10.4M Stock, Warrant Sale The proceeds from the sale will go toward the planned acquisition of Curetis and to support the ongoing submission of its technology to US regulators. Aug 13, 2019 Fulgent Genetics to Offer $75M of Securities Feb 8, 2019 Biocept Prices $7.5M Public Offering of Stocks, Warrants Dec 19, 2018 Biocept Reduces Number of Shares, Warrants for Public Offering Jul 27, 2018 OncoCyte Eyes $3.6M Raise in Securities Offering Jul 11, 2018 Biocept Prices Subscription Rights to Purchase $25M of Securities Nov 13, 2017 Precipio Completes Public Offering, Raises $2.7M Jul 25, 2017 OncoCyte Nets $5.7M From Exercise of Warrants Jun 29, 2017 OpGen Increases Public Offering to Up to $15.6M Jun 7, 2017 Interpace Files to Raise $10.5M Feb 21, 2017 OncoCyte Raises $2M Through Early Warrant Exercise Jan 3, 2017 Interpace Eyes $3.7M in Proceeds from Securities Purchase Deal May 20, 2016 Cancer Genetics Launches $5M Private Financing Dec 29, 2015 Great Basin Inks Deal to Sell $20.5M in Securities to Institutional Investors Sep 16, 2015 Great Basin Shares Fall on Plans to Restructure Warrants May 15, 2015 Nanosphere Closes $4.4M Financing Round, $30M Debt Facility Mar 4, 2015 Transgenomic Closes Public Offering of Stock, Warrants Mar 3, 2015 Great Basin Completes Follow-on Public Offering, Raises $20.5M in Net Proceeds Feb 13, 2015 CombiMatrix to Raise $4.9M from Direct Offering Feb 9, 2015 Biocept Amends Offering for up to $23M in Stock, Warrants Feb 3, 2015 GeneNews to Receive C$1.4M from Exercise of Warrants Load More Breaking News Rare Kidney Cancer Genomic Analysis Reveals Potential Target, Suggests Treatment SEC Concludes CareDx Investigation, Recommends No Enforcement Action Streck Quality Controls for DiaSorin's Luminex Sepsis Tests Receive FDA Clearance Adela Closes $48M Financing to Develop Cancer Monitoring, Early Detection Test 3EO Health At-Home Molecular COVID-19 Test Nabs FDA EUA The Scan Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants. Small Study of Gene Editing to Treat Sickle Cell Disease In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms. Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema. Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.